Source:http://linkedlifedata.com/resource/pubmed/id/12645908
Switch to
| Predicate | Object |
|---|---|
| rdf:type | |
| lifeskim:mentions | |
| pubmed:dateCreated |
2003-3-20
|
| pubmed:abstractText |
Three open-label, non-comparative, multicentre Phase II trials have examined the efficacy and tolerability of ZD0473 as first-and second-line therapy in non-small-cell lung cancer (NSCLC) patients and second-line therapy in small-cell lung cancer (SCLC) patients. Patients with second-line NSCLC or SCLC were evaluated as either platinum-sensitive or -resistant, based upon their time to relapse/progression after platinum-based therapy. First-line NSCLC patients (n = 18) received a total of 60 treatment cycles (median number per patient 2.5) whilst second-line NSCLC (n = 50) and SCLC (n = 48) patients both received a total of 127 treatment cycles (median number per patient 2.0). Grade 3/4 anaemia, neutropenia and thrombocytopenia was observed in: 38.8%, 22.2% and 27.7% of first-line NSCLC patients; 12.0%, 24.0% and 50% of second-line NSCLC patients; and 10.4%, 25.0% and 47.9% of second-line SCLC patients, respectively. The most common grade 3/4 non-haematological toxicities in all three trials were lethargy and dyspnoea. No clinically significant oto-, nephro- or neurotoxicity was observed. The first-line treatment of NSCLC produced an overall response rate (OR) of 6.3%. No OR was seen after second-line treatment of NSCLC, while ORs of 15.4% and 8.3% were seen in the platinum-resistant and -sensitive second-line SCLC patients, respectively.
|
| pubmed:language |
eng
|
| pubmed:journal | |
| pubmed:citationSubset |
IM
|
| pubmed:chemical | |
| pubmed:status |
MEDLINE
|
| pubmed:month |
Dec
|
| pubmed:issn |
0959-8049
|
| pubmed:author | |
| pubmed:issnType |
Print
|
| pubmed:volume |
38 Suppl 8
|
| pubmed:owner |
NLM
|
| pubmed:authorsComplete |
Y
|
| pubmed:pagination |
S13-8
|
| pubmed:dateRevised |
2007-11-15
|
| pubmed:meshHeading |
pubmed-meshheading:12645908-Adult,
pubmed-meshheading:12645908-Aged,
pubmed-meshheading:12645908-Aged, 80 and over,
pubmed-meshheading:12645908-Antineoplastic Agents,
pubmed-meshheading:12645908-Carcinoma, Non-Small-Cell Lung,
pubmed-meshheading:12645908-Clinical Trials, Phase II as Topic,
pubmed-meshheading:12645908-Disease-Free Survival,
pubmed-meshheading:12645908-Drug Resistance, Neoplasm,
pubmed-meshheading:12645908-Dyspnea,
pubmed-meshheading:12645908-Female,
pubmed-meshheading:12645908-Hematologic Diseases,
pubmed-meshheading:12645908-Humans,
pubmed-meshheading:12645908-Lung Neoplasms,
pubmed-meshheading:12645908-Male,
pubmed-meshheading:12645908-Middle Aged,
pubmed-meshheading:12645908-Multicenter Studies as Topic,
pubmed-meshheading:12645908-Organoplatinum Compounds,
pubmed-meshheading:12645908-Sleep Stages,
pubmed-meshheading:12645908-Treatment Outcome
|
| pubmed:year |
2002
|
| pubmed:articleTitle |
ZD0473 treatment in lung cancer: an overview of the clinical trial results.
|
| pubmed:affiliation |
Fox Chase Temple University Cancer Center, Philadelphia, PA, USA. treatja@tuhs.temple.edu
|
| pubmed:publicationType |
Journal Article,
Meta-Analysis
|